Actively Recruiting

Age: 18Years +
All Genders
ID06842316

In Vitro Effects of Phytocannabinoids on Immune Response and Autophagy During Chronic Immune-mediated Inflammatory Diseases

Led by Centre Hospitalier Régional d'Orléans · Updated on 2025-12-30

100

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

This research aims to explore how phytocannabinoids, natural molecules from the cannabis plant, affect the immune system and autophagy in people with chronic immune-mediated inflammatory diseases (IMIDs). These diseases, including rheumatoid arthritis, spondyloarthropathy, psoriatic arthritis, Sjogren's disease, and systemic lupus erythematosus, involve inflammation caused by immune system imbalance. The study focuses on identifying the most effective chemical profiles of phytocannabinoids to influence these inflammatory conditions. The study involves collecting a single 40 mL blood sample from 100 patients with these IMIDs during routine care. Blood cells will be exposed in the lab to different full-spectrum phytocannabinoid extracts, including CBD-dominant with low THC, THC-dominant, balanced THC/CBD, and CBG-dominant extracts. Inflammatory inducers will be used alone and with these extracts, alongside a known anti-inflammatory drug as a control, to assess their effects on immune cell responses. Participants will provide consent and have blood collected once. Researchers will analyze inflammatory markers, cannabinoid receptor expression, and genes related to autophagy and apoptosis in blood cells. The main goal is to understand how different phytocannabinoid mixtures affect the inflammatory profile of immune cells. This cross-sectional study does not involve ongoing treatment or follow-up, focusing instead on lab-based immune response measures.

CONDITIONS

Brief Title

Effects of Phytocannabinoids on Immune Response and Autophagy During Chronic Immune-mediated Inflammatory Diseases

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male or female aged 18 years or older
  • Diagnosis confirmed by a rheumatologist of rheumatoid arthritis, spondyloarthropathy (with or without inflammatory bowel disease), psoriatic arthritis (with or without active psoriasis), systemic lupus erythematosus, or Sjogren's disease
  • Provided consent to participate in the study
  • Affiliated to social security
  • Receiving authorized routine care treatments including NSAIDs, level 1 to 3 analgesics, local corticosteroids, oral corticosteroids (daily dose up to 15 mg), 5-aminosalicylic acid, salazopyrine, methotrexate, leflunomide, hydroxychloroquine, biotherapies, or targeted therapies
Not Eligible

You will not qualify if you...

  • Received intravenous corticosteroid therapy less than 4 weeks ago
  • Taking oral corticosteroids with a daily dose higher than 15 mg
  • Using CBD or recreational cannabis, or testing positive for cannabis or CBD in saliva
  • Pregnant or breastfeeding women
  • Under guardianship or curatorship

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person) including consent and eligibility verification with a saliva test

Sample Collection

Duration - One-time procedure at inclusion

Participants provide an additional 40 mL blood sample during a routine blood test for research purposes. Blood cells from participants are exposed in vitro to various inflammatory inducers and different phytocannabinoid extracts to evaluate biological and immunological effects.

1 visit (in-person) concurrent with a routine blood test

Trial Site Locations

Total: 1 location

1

CHU d'ORLEANS

Orléans, France, 45067

Actively Recruiting

Loading map...

Research Team

C

Carine Pr SALLIOT, PhD

F

Fanny LOUAT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

5

Similar Trials

A Phase 2b Randomized, Double-Blind, Placebo-Controlled Stud...

Arthritis, Rheumatoid

Actively Recruiting

62 locations

Epidemiology, Treatment Patterns, and Healthcare Resource Us...

Inflammatory Bowel Diseases

Actively Recruiting

1 location

A Phase 3, Multicenter, Open-label, Long-term Extension Stud...

Crohns Disease

Actively Recruiting

42 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Published Research Related To This Trial

The effectiveness of cannabinoids in the management of chronic nonmalignant neuropathic pain: a systematic review.

Darrell G Boychuk, Greg Goddard, Giovanni Mauro...

https://pubmed.ncbi.nlm.nih.gov/25635955

Oral cannabinoids in people living with HIV on effective antiretroviral therapy: CTN PT028-study protocol for a pilot randomised trial to assess safety, tolerability and effect on immune activation.

Cecilia T Costiniuk, Zahra Saneei, Jean-Pierre Routy...

https://pubmed.ncbi.nlm.nih.gov/30659041

Therapeutic and clinical foundations of cannabidiol therapy for difficult-to-treat seizures in children and adults with refractory epilepsies.

Doodipala Samba Reddy

https://pubmed.ncbi.nlm.nih.gov/36206806